Endometrial cancer, estrogens and metabolic syndrome: Scenario becomes more complicated

Voprosy Onkologii

Volumn 60, Issue 3, 2014, Pages 254-262

  Berstein, L M ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

Aromatase; CYP17 and m TOR inhibitors; Endometrial cancer; Epidemiology; Estrogens; Insulin resistance; Mechanisms of hormonal carcinogenesis; Metabolic syndrome; Metformin; Obesity; PTEN gene; Risk factors

Indexed keywords

ESTROGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ORAL CONTRACEPTIVE AGENT; PTEN PROTEIN, HUMAN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

CANCER RISK; ENDOCRINOLOGIST; ENDOMETRIUM CANCER; FEMALE; GENE MUTATION; GENETIC DAMAGE; HORMONAL CARCINOGENESIS; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; MORBIDITY; REVIEW; DIABETES MELLITUS; ENDOMETRIUM TUMOR; GENETICS; METABOLISM; MUTATION; OBESITY; PHENOTYPE; RISK FACTOR;

ANTINEOPLASTIC AGENTS, HORMONAL; CONTRACEPTIVES, ORAL, HORMONAL; DIABETES COMPLICATIONS; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MUTATION; OBESITY; PHENOTYPE; PTEN PHOSPHOHYDROLASE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84905925280     PISSN: 05073758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Allen N.E., Key T.J., Dossus L. et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC) // Endocr Relat Cancer. - 2008. - Vol. 15 (2). - P. 485-497. Doi: 10.1677/ERC-07-0064.
2. Altman A.D., Thompson J., Nelson G. et al. Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study // J. Obstet. Gynaecol Can. - 2012. - Vol. 34 (7). - P. 664-672.
3. Armstrong B. Endocrine factors in human carcinogenesis. IARC Sci Publ. - 1982. - N39. - P. 193-221.
4. Audet-Walsh E., Lepine J., Gregoire J. et al. Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics // J Clin Endocrinol Metab. - 2011. - Vol. 96 (2). - E 330-339. Doi: 10.1210/jc.2010-2050.
5. Bansal N., Yendluri V, Wenham R.M. et al. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies // Cancer Control. - 2009. - Vol. 16 (1). - P. 8-13.
6. Berstein LM. Metformin in obesity, cancer and aging: addressing controversies // Aging (Albany NY). - 2012. - Vol. 4339 (5). - P. 320-329.
7. Berstein LM. Cancer and heterogeneity of obesity: a potential contribution of brown fat // Future Oncol. - 2012. - Vol. 8 (12). - P. 1537-1548. Doi: 10.2217/fon.12.150.
8. Berstein LM. High baby birth weight and risk of hormone-associated cancer in mothers: the cancer-cardiovascular disease dichotomy and its possible causes // Womens Health (Lond Engl). - 2013. - Vol. 9 (4). - P. 361-371. Doi: 10.2217/whe. 13.29.
9. Berstein L.M., Imyanitov E.N., Gamajunova V.B. et al. CYP17 genetic polymorphism in endometrial cancer: are only steroids involved? // Cancer Lett. - 2002. - Vol. 180 (1). - P. 47-53.
10. Berstein L, Kovalevskij A., Zimarina T. et al. Aromatase and comparative response to its inhibitors in two types of endometrial cancer // J. Steroid Biochem. Mol. Biol. - 2005. -Vol. 95 (1-5). - P. 71-74.
11. Berstein L, Zimarina T., Imyanitov E. et al. Hormonal imbalance in two types of endometrial cancer and genetic polymorphism of steroidogenic enzymes // Maturitas. - 2006. - Vol. 54 (4). - P. 352-355.
12. Berthelsen H., Svane H. Cancer of the endometrium and hyperestrinism; two different modes of origin of endometrial cancer // Dan. Med. Bull. - 1956. - Vol. 3 (8). - P. 236-239.
13. Bokhman J.V Two pathogenetic types of endometrial carcinoma // Gynecol Oncol. - 1983. - Vol. 15. - P. 10-17.
14. Bulun S.E., Mahendroo M.S., Simpson E.R. Polymerase chain reaction amplification fails to detect aromatase cytochrome P450 transcripts in normal human endometrium or decidua // J. Clin. Endocrinol. Metab. - 1993. - Vol. 76 (6). - P. 1458-1463.
15. Bulun S.E., Economos K., Miller D., Simpson E.R. CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors // J. Clin. Endocrinol. Metab. - 1994. - Vol. 79 (6). - P. 1831-1834.
16. Cancer Genome Atlas Research Network, Kandoth C, Schultz N. et al. Integrated genomic characterization of endometrial carcinoma // Nature. - 2013. - Vol. 497 (7447). - P. 67-73. Doi: 10.1038/nature12113.
17. Cavalieri E., Rogan E. Catechol quinones of estrogens in the initiation of breast, prostate, and other human cancers: keynote lecture // Ann N Y Acad Sci. - 2006. - Vol. 1089. - P. 286-301.
18. De Vivo I., Prescott J., Setiawan V.W. et al. Genome-wide association study of endometrial cancer in E2C2 // Hum. Genet. - 2014. - Vol. 133 (2). - P. 211-224. Doi: 10.1007/S00439-013-1369-1.
19. Delias A., Jundt G., Sartorius G. et al. Combined PTEN and p27kip1 protein expression patterns are associated with obesity and prognosis in endometrial carcinomas // Clin. Cancer Res. - 2009. - Vol. 15 (7). - P. 2456-2462. Doi: 10.1158/1078-0432.CCR-08-1732.
20. Dossus L, Lukanova A., Rinaldi S. et al. Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort-a factor analysis // Am J Epidemiol. - 2013. - Vol. 177 (8). - P. 787-799. Doi: 10.1093/aje/kws309.
21. Erol A. Systemic DNA damage response and metabolic syndrome as a premalignant state // Curr Mol Med. - 2010. - Vol. 10 (3). - P. 321-334.
22. Esposito K., Chiodini P., Capuano A. et al. Metabolic syndrome and endometrial cancer: a meta-analysis // Endocrine. - 2014. - Vol. 45 (1). - P. 28-36. Doi: 10.1007/ s12020-013-9973-3.
23. Esposito K., Chiodini P., Colao A. et al. Metabolic syndrome and risk of cancer: a systematicreview and metaanalysis // Diabetes Care. - 2012. - Vol. 35 (11). - P. 2402-2411. Doi: 10.2337/dc12-0336.
24. Evans T., Sany O., Pearmain P. et al. Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006 // Br. J. Cancer. - 2011. - Vol. 104 (9). - P. 1505-1510. Doi: 10.1038/bjc.2011.68.
25. Fadare O. Is there an association between type II endometrial carcinomas and breast cancers? A critical appraisal // Womens Health (Lond Engl). - 2013. - Vol. 9 (4). - P. 315-317. Doi: 10.2217/whe.13.27.
26. Felix A.S., Weissfeld J.L., Stone R.A. et al. Factors associated with Type I and Type II endometrial cancer // Cancer Causes Control. - 2010. - Vol. 21 (11). - P. 1851-1856.
27. Fremont-Smith M., Meigs J.V., Graham R.M., Gilbert H.H. Cancer of endometrium and prolonged estrogen therapy //J. Am. Med. Assoc. - 1946. - Vol. 131 (10). P. 805-808.
28. Friedenreich CM., Langley A.R., Speidel TP. et al. Case-control study of inflammatory markers and the risk of endometrial cancer // Eur. J. Cancer Prev. - 2013. - Vol. 22 (4). - P. 374-379. Doi: 10.1097/ CEJ.0b013e32835b3813.
29. Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia // Cochrane Database Syst Rev. - 2012. - 8:CD000402. Doi: 10.1002/14651858. CD000402.pub4.
30. Furuta H., Furuta M., Sanke T. et al. Nonsense and mis-sense mutations in the human hepatocyte nuclear factor-1 beta gene (TCF2) and their relation to type 2 diabetes in Japanese // J. Clin. Endocrinol. Metab. - 2002. - Vol. 87 (8). - P. 3859-3863. Doi:10.1210/jc.87.8.3859
31. Garrett A., Quinn M.A. Hormonal therapies and gynaecological cancers // Best Pract. Res. Clin. Obstet. Gynaecol. - 2008. - Vol. 22 (2). - P. 407-421.
32. Hersberger M., von Eckardstein A. Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport // Handb. Exp. Pharmacol. - 2005. - Vol. 170. - P. 537-561.
33. Huang M., Djordjevic B., Yates M.S. et al. Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome // Cancer. - 2013. - Vol. 119 (16). - P. 3027-3033. Doi: 10.1002/cncr.28152.
34. Iglesias D.A., Yates M.S., van der Hoeven D. et al. Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy // Mol. Cancer Ther. - 2013. - Vol. 12 (12). - P. 2847-2856. doi: 10.1158/1535-7163.MCT-13-0439.
35. Jarzabek K., Koda M., Walentowicz-Sadlecka M. et al. Altered expression of Ers, aromatase, and COX2 connected to estrogen action in type 1 endometrial cancer biology // Tumour Biol. -2013. - Vol. 34 (6). - P. 4007-4016. Doi: 10.1007/sl 3277-013-0991-9.
36. Jones H.A., Hahnel R. Specificity of the Kober Reaction // Nature. -1967. - Vol. 215. - P. 1381-1382. Doi:10.1038/2151381a0
37. Jongen V.H., Thijssen J.H., Hollema H. et al. Is aromatase cytochrome P450 involved in the pathogenesis of endometrioid endometrial cancer? // Int. J. Gynecol. Cancer. - 2005. - Vol. 15. - P. 529-536.
38. Kim T., Park H., Yue W. et al. Tetra-methoxystilbene modulates ductal growth of the developing murine mammary gland // Breast Cancer Res. Treat. - 2011. - Vol. 126 (3). - P. 779-789. doi: 10.1007/s10549-010-1301-5.
39. Lepine J., Bernard O., Plante M. et al. Specificity and re-gioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium // J. Clin. Endocrinol. Metab. -2004. - Vol. 89 (10). - P. 5222-5232.
40. Liehr J.G. Genotoxicity of the steroidal oestrogens oes-trone and oestradiol: possible mechanism of uterine and mammary cancer development // Hum. Reprod. Update. - 2001. - Vol. 7 (3). - P. 273-281.
41. Liu FS. Molecular carcinogenesis of endometrial cancer // Taiwan J Obstet Gynecol. - 2007. - Vol. 46 (1). -P. 26-32.
42. Lu K.H., Loose D.S., Yates M.S. et al. Prospective multi-center randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome // Cancer Prev Res (Phila). - 2013. - Vol. 6 (8). - P. 774-781. Doi: 10.1158/1940-6207.CAPR-13-0020.
43. Martin-Hirsch P.P., Bryant A., Keep S.L. et al. Adjuvant progestagens for endometrial cancer // Cochrane Database Syst. Rev. - 2011. - 6:CD001040. Doi: 10.1002/14651858.CD001040.pub2
44. Nelson H.D., Humphrey LL, Nygren P. et al. Postmenopausal hormone replacement therapy: scientific review // JAMA. - 2002. - Vol. 288 (7). - P. 872-881.
45. Pathirage N. Di Nezza LA., Salmonsen LA. et al. Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer // Fertil. Steril. - 2006. - Vol. 86 (2). - P. 469-472.
46. Ray-Coquard I., Favier L, Weber B. et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO // Br. J. Cancer. - 2013. - Vol. 108 (9). - P. 1771-1777. Doi: 10.1038/bjc.2013.183.
47. Rosenblum J., Hendricks C.H. Estrogenated vaginal epithelium; relationship to the development of carcinoma of the endometrium // Obstet.Gynecol. - 1954. - Vol. 3 (5). - P. 535-545.
48. Salama S.A., Kamel M.W., Diaz-Arrastia C.R. et al. Effect of tumor necrosis factor-alpha on estrogen metabolism and endometrial cells: potential physiological and pathological relevance // J. Clin. Endocrinol. Metab. - 2009. - Vol. 94 (1). - P. 285-293.
49. Schindler A.E. Progestogen deficiency and endometrial cancer risk // Maturitas. - 2009. - Vol. 62 (4). - P. 334-337. Doi: 10.1016/j.maturitas.2008.12.018.
50. SEER Stat Fact Sheets: Endometrial Cancer. http://seer.cancer.gov/stat-facts/html/corp.html
51. Setiawan V.W., Yang H.P., Pike M.C. et al. Type I and II endometrial cancers: have they different risk factors? // J. Clin. Oncol. - 2013. - Vol. 31 (20). - P. 2607-2018. Doi: 10.1200/JCO.2012.48.2596.
52. Sherman METheories of endometrial carcinogenesis: a multidisciplinary approach // Mod. Pathol. - 2000. - Vol. 13 (3). - P. 295-308.
53. Sørlie T., Perou CM., Tibshirani R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications // Proc. Natl. Acad. Sci USA. - 2001. - Vol. 98 (19). - P. 10869-10874.
54. Watanabe K., Sasano H., Harada N. et al. Aromatase in human endometrial carcinoma and hyperplasia, immu-nohistochemical, in situ hybridization, and biochemical studies // Am. J. Pathol. - 1995. - Vol. 146. - P. 491-500.
55. Yang H.P., Wentzensen N. Trabert B. et al. Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study // Am J Epidemiol. - 2013. - Vol. 177 (2). - P. 142-151. Doi: 10.1093/aje/kws200.
56. Yin L, Hu Q. CYP17 inhibitors-abiraterone, C17,20-lyase inhibitors and multi-targeting agents // Nat Rev Urol. - 2014. - Vol. 11(1):32-42. Doi: 10.1038/nrurol.2013.274.